AstraZeneca, other trouble besides Covid vaccine.

Markets have been negatively affected by the new tested cancer drug launched by the pharmaceutical giant. The drug, generated by studying a monoclonal antibody against cancer, has in fact disappointed expectations causing important repercussions on the share value.

Gianluca Cambareri of Tonucci & Partners, expert in commercial law and capital market, was interviewed by Panorama.


Per non perderti le novità e gli approfondimenti di Tonucci & Partners, iscriviti alle nostre newsletter

    I have read the Privacy Policy
    and i authorized the treatment of my personal data